{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:30:06Z","timestamp":1794025806428,"version":"4.8.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Mirabegron, the first \u03b2-3 adrenergic receptor agonist, received approval from the Food and Drug Administration (FDA) in 2012 for the treatment of overactive bladder (OAB). This pharmacovigilance study investigated the safety profile of mirabegron treatment using the US FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study employed disproportionality analyses, including the reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) algorithm, to quantify signals of adverse events associated with mirabegron.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> From the first quarter of 2012 to the third quarter of 2023, a comprehensive total of 14,356,234 adverse event (AE) reports were submitted to the FDA Adverse Event Reporting System database. Within this dataset, encompassing 18,763 reports specifically associated with mirabegron, healthcare professionals notably contributed 2,902 of these reports. A total of 80 preferred terms (PTs) of interest were identified using both the ROR and information component algorithms. The most common AEs included blood pressure increased, urinary retention, atrial fibrillation, dry mouth, and tachycardia, which were consistent with the product instructions. Unexpected significant AEs, such as arrhythmia, palpitations, dementia, transient ischemic attack, Parkinson\u2019s disease, anti-neutrophil cytoplasmic antibody positive vasculitis, lip swelling, and swollen tongue, were also identified. The study findings indicated that the majority of onset time occurred within 30\u00a0days (n = 358, 55.68%). However, AEs were still possible after 1\u00a0year of mirabegron treatment.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study provided valuable evidence for the real-world safety of mirabegron, helping clinical professionals enhance their understanding of mirabegron\u2019s safety in clinical practice. It also contributed valuable evidence for further safety studies on mirabegron.<\/jats:p>","DOI":"10.3389\/fphar.2024.1376535","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:54:14Z","timestamp":1710737654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"15","author":[{"given":"Junwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ijo.2009.54","article-title":"Beta3-adrenoceptor function and long-term changes in body weight","volume":"33","author":"Andersson","year":"2009","journal-title":"Int. J. Obes."},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/TCRM.S33052","article-title":"New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA","volume":"9","author":"Andersson","year":"2013","journal-title":"Ther. Clin. Risk Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejogrb.2015.02.020","article-title":"The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder","volume":"187","author":"Balachandran","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther. Adv. Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1111\/bph.14433","article-title":"\u03b23 -Adrenoceptor stimulation of perivascular adipocytes leads to increased fat cell-derived NO and vascular relaxation in small arteries","volume":"175","author":"Bussey","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3892\/etm.2022.11656","article-title":"Mirabegron, a \u03b23-adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently","volume":"24","author":"Chan","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.3390\/jcm12216783","article-title":"Percutaneous tibial nerve stimulation in the treatment of refractory idiopathic overactive bladder syndrome: a retrospective cohort study","volume":"12","author":"Frey","year":"2023","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00192-016-3003-y","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP)","volume":"27","author":"Haylen","year":"2016","journal-title":"Int. Urogynecol J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b2\u2083 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/ntr\/nty116","article-title":"Nicotinic acetylcholine receptor agonists for the treatment of Alzheimer's dementia: an update","volume":"21","author":"Hoskin","year":"2019","journal-title":"Nicotine Tob. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.purol.2021.05.005","article-title":"Adverse events associated with mirabegron 50mg versus placebo: a systematic review and meta-analysis","volume":"31","author":"Hou","year":"2021","journal-title":"Prog. Urol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis","volume":"19","author":"Javed","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1109\/TCBB.2019.2928305","article-title":"Improved adverse drug event prediction through information component guided pharmacological Network model (IC-pnm)","volume":"18","author":"Ji","year":"2021","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform"},{"key":"B14","first-page":"1161","article-title":"Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia","volume":"117","author":"Jia","year":"2004","journal-title":"Chin. Med. J. Engl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1517\/17425255.2013.786700","article-title":"The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option","volume":"9","author":"Kashyap","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vascn.2017.04.008","article-title":"Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron","volume":"87","author":"Korstanje","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11255-020-02774-7","article-title":"Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity","volume":"53","author":"Krhut","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/tcmj.tcmj_167_20","article-title":"How to choose appropriate medication for overactive bladder: findings from the largest integrated clinical trial database analysis of mirabegron studies","volume":"34","author":"Kuo","year":"2022","journal-title":"Tzu Chi Med. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/tcmj.tcmj_209_21","article-title":"Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients","volume":"35","author":"Kuo","year":"2023","journal-title":"Tzu Chi Med. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12894-023-01329-z","article-title":"Associations between overactive bladder and sleep patterns: a cross-sectional study based on 2007-2014 NHANES","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Urol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/clpt.2012.181","article-title":"Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-and active-controlled thorough QT study","volume":"92","author":"Malik","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.rmcr.2019.02.012","article-title":"Respiratory dysfunction following initiation of mirabegron: a case report","volume":"26","author":"Malsin","year":"2019","journal-title":"Respir. Med. Case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2016.03.009","article-title":"Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPi)","volume":"27","author":"Murchison","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"","journal-title":"J. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"","journal-title":"Int. J. Clin. Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b2\u2083-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"","journal-title":"J. Urol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3390\/pharmaceutics13101531","article-title":"Verification of the \"upward variation in the reporting odds ratio scores\" to detect the signals of drug-drug interactions","volume":"13","author":"Noguchi","year":"2021","journal-title":"Pharmaceutics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1145860","DOI":"10.3389\/fphar.2023.1145860","article-title":"Periprostatic adipose tissue (PPAT) supernatant from obese mice releases anticontractile substances and increases human prostate epithelial cell proliferation: the role of nitric oxide and adenosine","volume":"14","author":"Passos","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0169-328x(94)00274-i","article-title":"Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain","volume":"29","author":"Rodriguez","year":"1995","journal-title":"Brain Res. Mol. Brain Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","article-title":"Cardiovascular safety of \u03b23-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome","volume":"69","author":"Rosa","year":"2016","journal-title":"Eur. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1006\/brcg.1998.1035","article-title":"Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body Dementia: too much or too little cortical acetylcholine","volume":"38","author":"Sarter","year":"1998","journal-title":"Brain Cogn."},{"key":"B33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-0043-1770093","article-title":"Mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis","volume":"45","author":"Sartori","year":"2023","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"i46","DOI":"10.1093\/ndt\/gfu398","article-title":"Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014","volume":"30","author":"Sch\u00f6nermarck","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"F388","DOI":"10.1152\/ajprenal.00392.2016","article-title":"Inhibition of cholinergic neurotransmission by \u03b23-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders","volume":"313","author":"Silva","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s12603-023-1972-3","article-title":"The role of sarcopenia in overactive bladder in adults in the United States: retrospective analysis of NHANES 2011-2018","volume":"27","author":"Song","year":"2023","journal-title":"J. Nutr. Health Aging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2478\/rir-2023-0003","article-title":"Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Sun","year":"2023","journal-title":"Rheumatol. Immunol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/luts.12335","article-title":"Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: a Japanese post-marketing study","volume":"13","author":"Takahashi","year":"2021","journal-title":"Low. Urin Tract. Symptoms"},{"key":"B42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jdcr.2019.04.010","article-title":"Serum sickness-like reaction associated with mirabegron","volume":"5","author":"Tan","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"17474930231215277","DOI":"10.1177\/17474930231215277","article-title":"Identifying the optimal time period for detection of atrial fibrillation after ischaemic stroke and TIA: an updated systematic review and meta-analysis of randomized control trials","author":"Thakur","year":"2023","journal-title":"Int. J. Stroke"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/jcph.952","article-title":"An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects","volume":"57","author":"van Gelderen","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1097\/CM9.0000000000000539","article-title":"Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"132","author":"Weng","year":"2019","journal-title":"Chin. Med. J. Engl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1137191","DOI":"10.3389\/fpubh.2023.1137191","article-title":"A positive association between the prevalence of circadian syndrome and overactive bladder in United States adults","volume":"11","author":"Xiao","year":"2023","journal-title":"Front. Public Health"},{"key":"B48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23 -adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low. Urin Tract. Symptoms"},{"key":"B49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00737-023-01378-1","article-title":"Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)","volume":"27","author":"Zhang","year":"2023","journal-title":"Arch. Womens Ment. Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/00185787221095737","article-title":"Mirabegron associated angioedema: a case report","volume":"57","author":"Zuchowski","year":"2022","journal-title":"Hosp. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1376535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:54:19Z","timestamp":1710737659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1376535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1376535"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1376535","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"article-number":"1376535"}}